BioPharma Resources

Drug Trial Radar · NCT06112379

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,902 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,902

Actual

Start

Nov 14, 2023

Primary completion

Nov 20, 2028

Study completion Sep 23, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Dato-DXdDrug

    Experimental drug IV infusion

  • DurvalumabDrug

    Experimental drug IV Infusion

  • PembrolizumabDrug

    IV Infusion Active comparator

  • DoxorubicinDrug

    IV infusion Experimental/Active Comparator

  • EpirubicinDrug

    IV Infusion Experimental/Active Comparator

  • CyclophosphamideDrug

    IV infusion Experimental/Active Comparator

  • PaclitaxelDrug

    IV infusion Experimental/Active Comparator

  • CarboplatinDrug

    IV infusion Experimental/Active Comparator

  • CapecitabineDrug

    Tablet Oral route of administration Experimental/Active Comparator

  • OlaparibDrug

    Tablet Oral route of administration Experimental/Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS) in the experimental vs control armsTime frame: Date of randomization to date of the EFS event, up to 93 months after the first subject randomized

Locations

283 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Daphne, Alabama

  • Research Site

    Prescott, Arizona

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Rogers, Arkansas

  • Research Site

    Los Angeles, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Torrance, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Longmont, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    New Haven, Connecticut

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Des Moines, Iowa

  • Research Site

    Edgewood, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Annapolis, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Traverse City, Michigan

  • Research Site

    Burnsville, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Columbia, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    East Brunswick, New Jersey

  • Research Site

    New Brunswick, New Jersey

  • Research Site

    Santa Fe, New Mexico

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Blue Ash, Ohio

  • Research Site

    Eugene, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

Showing 40 of 283 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.